{"id":1525,"date":"2013-08-28T21:23:54","date_gmt":"2013-08-28T21:23:54","guid":{"rendered":"https:\/\/consulting.vamtam.com\/?p=1525"},"modified":"2023-11-04T13:23:20","modified_gmt":"2023-11-04T12:23:20","slug":"pharma-case","status":"publish","type":"post","link":"https:\/\/acc-company.com\/en\/pharma-case\/","title":{"rendered":"Pharmaceutical Industry"},"content":{"rendered":"
\n

\n\t\tPioneering the Future in Pharmaceuticals\n\t<\/h1>\n\t

Aus GMP-Sicht muss eine kontinuierliche Verifizierung und damit Pr\u00fcfung der Qualit\u00e4t von Arzneimitteln erfolgen. Aber bedeutet das, dass man mehrere Millionen Euro pro Jahr f\u00fcr Pr\u00fcfungen ausgeben muss? Oder dass dies zwangsl\u00e4ufig in zerst\u00f6renden Pr\u00fcfungen verkaufsf\u00e4higer Produkte erfolgen muss? Gibt es keinen anderen Weg? Wir sagen: Den gibt es! Und er f\u00fchrt \u00fcber \u201eparametrische Freigaben“. I4.0 in einer pharmazeutischen Umgebung? Mit AC&C geht das!<\/p>\n\t\t\t\t\t\t\t\"Quality\t\t\t\t\t\t\t\n

\n\t\tChallenge\n\t<\/h2>\n\t

Traditional batch releases in the pharmaceutical industry heavily rely on costly and time-consuming destructive testing methods. The expenses associated with these approval processes can quickly escalate to thousands of euros per test, depending on the specific drug. Our mission is to introduce a paradigm shift by enabling releases based on product and production parameters, eliminating the need for destructive testing altogether. Join us in embracing a more efficient and cost-effective approach to batch releases without compromising on quality.<\/p>\n

\n\t\tSolution\n\t<\/h2>\n\t

When seeking approval for an application device, we analyze the product and production data obtained from critical production runs to assess their predictability in relation to the quality of the end product. By leveraging advanced data analysis techniques, we provide insights that enable a more accurate evaluation of product quality during the approval process. Embrace our solution to enhance predictability and streamline the path to successful approvals for your application devices.<\/p>\n\t\t\t\t\t\t\t\"Scientists\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"A\t\t\t\t\t\t\t\n

\n\t\tResults\n\t<\/h2>\n\t

Our comprehensive studies have empowered the pharmaceutical company to significantly reduce, and in some cases eliminate, the need for destructive testing. This breakthrough approach has led to remarkable cost savings, with testing and scrap costs slashed by up to 80%. Embrace our solution to unlock unparalleled efficiency and cost optimization in your pharmaceutical operations.<\/p>\n

\n\t\tMore Cases\n\t<\/h2>\n\t